Fig. 4: Ad26 vaccine–elicited vector-immunity has a minor impact on humoral immune responses induced by a first dose of the B-series in cynomolgus macaques.

Binding serum antibody concentrations were measured by ELISA for each regimen specific for EBOV glycoprotein (GP) (a, b), SUDV GP (c), HIV Env Clade C (d), and HIV Env Mos1 (e). Shown are geometric group means of the log10 EU/mL values determined relative to an assay standard. Dotted lines represent the LLoD/LLoQ. For (a, b), the LLoQ of the human assay of 1.62log10 was used. For (c), the LLoD was defined as 1.48log10 (EU/mL), which was measured for the pre-dosing samples in the SUDV GP–specific assay³⁶. For (d, e), the LLoQ of the human assay of 2.19log10 was used, whereas the ULoQ of the human assay was 3.69log10³¹. The fold-change in antibody concentrations is depicted in (f) and corresponds to the change in response comparing pre–dose 1 to peak response post–dose 1 per animal. “Ad26rep” refers to animals vaccinated in the A-series, and “Ad26” refers to animals that were not vaccinated during the A-series. Pairwise comparison of the difference between pre-exposed animals and unexposed animals per time point was performed for data in (a–e), summarized in Supplementary Table 2. An ANOVA was performed over the fold-changes per study and across the 3 studies over the data shown in (f), summarized in Supplementary Table 3.